En Carta Diagnostics announced a €5 million funding round to advance its molecular diagnostics platform and support its commercial launch. The round combines investment led by Blue Forest Ventures, participation from Ring Capital, and support from existing investors CentraleSupélec Venture and 50 Partners Health. The financing also includes non-dilutive funding from Bpifrance and other partners.
En Carta Diagnostics will use the funding to accelerate regulatory certification in Europe and the U.S. The company also plans to scale industrialization of its molecular diagnostic platform and prepare for commercialization.
The company’s initial commercial focus is early Lyme disease detection. En Carta Diagnostics said current tests can require patients to wait weeks before producing reliable answers, creating a need for faster and more accessible diagnostic tools.
En Carta Diagnostics is developing technology designed to deliver laboratory-grade molecular testing in a simple at-home format. The company said its platform is designed to provide results in around 30 minutes.
The new financing follows several recent milestones for the company. Over the past six months, En Carta Diagnostics received FDA Breakthrough Device Designation and signed a €13 million commercial partnership with AAZ-LMB.
Together, the funding, regulatory progress, and commercial partnership are intended to help bring a new generation of molecular diagnostics closer to patients. The company’s broader goal is to make fast and reliable molecular diagnostics available where and when patients need them most.
En Carta Diagnostics said the new capital will help it move from development toward regulatory certification, industrial scale-up, and commercial launch as it builds its first product around Lyme disease testing.
